Skip to main content
Premium Trial:

Request an Annual Quote

Biocept BRAF Liquid Biopsy Test

Biocept has launched a blood-based BRAF mutation test to help physicians identify melanoma patients who might benefit from currently available targeted therapies. According to the company, because of the high sensitivity of the assay, it could also be used to monitor patients' response to treatment and the progression of disease during the course of therapy.

A quantitative assay, the BRAF test joins Biocept's existing portfolio of liquid biopsy tests for breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.